Inhibikase Therapeutics
IKT
9 hedge funds and large institutions have $975K invested in Inhibikase Therapeutics in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
80% more funds holding
Funds holding: 5 → 9 (+4)
4% more capital invested
Capital invested by funds: $936K → $975K (+$39K)
0.05% more ownership
Funds ownership: 0.22% → 0.27% (+0.05%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$120K |
| 2 |
HF
HRT Financial
New York
|
+$78.4K |
| 3 |
Millennium Management
New York
|
+$75.7K |
| 4 |
BlackRock
New York
|
+$3.85K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$79K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$20.2K |
| 3 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Fidelity Investments
Boston,
Massachusetts
| $601K | – | – | – |
|
|
ZCA
2
Zeke Capital Advisors
Berwyn,
Pennsylvania
| $113K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $107K | +$120K | +2,976 | New |
|
|
HF
4
HRT Financial
New York
| $69K | +$78.4K | +1,936 | New |
|
|
5
Millennium Management
New York
| $67K | +$75.7K | +1,871 | New |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $12K | -$20.2K | -500 | -60% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $3K | +$3.68K | +91 | New |
|
|
8
BlackRock
New York
| $3K | +$3.85K | +95 | New |
|
|
MS
9
Maven Securities
St Helier,
Jersey
| – | -$79K | -1,833 | Closed |
|
|
NFSG
10
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$2K | -42 | Closed |
|
11
Wells Fargo
San Francisco,
California
| – | +$81 | +2 | New |
|
IKT Hedge Fund Activity: Q1 2021 in Review
9 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2021, worth a combined $975K — up 4.2% from $936K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IKT positions and 2 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $120K. The largest seller was Maven Securities, exiting entirely with an estimated $79K sold.
- 9 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2021, up from 5 in Q4 2020.
- Funds reported $975K of Inhibikase Therapeutics stock for Q1 2021, up 4.2% quarter-over-quarter.
- 6 funds opened new Inhibikase Therapeutics positions in Q1 2021 and 2 closed out, a net change of +4 holders.
- The largest Inhibikase Therapeutics buyer in Q1 2021 was Citadel Advisors, an estimated $120K added.
- The largest Inhibikase Therapeutics seller in Q1 2021 was Maven Securities, an estimated $79K sold.
Based on aggregated 13F filings for Q1 2021.